RVMD: Revolution Medicines, Inc.
About
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Current Value
$56.251 Year Return
Current Value
$56.251 Year Return
Key Details
Market Cap
$9.50B
P/E Ratio
-15.72
1Y Stock Return
171.62%
1Y Revenue Growth
-97.16%
Dividend Yield
0.00%
Price to Book
6.0
Strategies that include RVMD
Stock's related to RVMD
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| AJX | 48.99% | $137.63M | -33.99% | 9.24% |
| KYMR | 45.19% | $2.77B | +125.95% | 0.00% |
| IDYA | 43.85% | $2.24B | -15.21% | 0.00% |
| PGEN | 43.24% | $228.91M | -28.00% | 0.00% |
| ACLX | 41.93% | $4.74B | +69.19% | 0.00% |
| IMVT | 41.74% | $3.70B | -23.48% | 0.00% |
| RCKT | 40.58% | $1.20B | -39.83% | 0.00% |
| NMAI | 39.81% | - | - | 13.12% |
| AGYS | 39.55% | $3.44B | +39.55% | 0.00% |
| DAWN | 39.30% | $1.36B | +13.42% | 0.00% |
| AGNC | 39.22% | $8.56B | +9.64% | 14.95% |
| RYTM | 39.09% | $3.69B | +79.50% | 0.00% |
| AVXL | 39.05% | $698.71M | +22.62% | 0.00% |
| MEDP | 38.34% | $9.79B | +14.00% | 0.00% |
| KN | 38.19% | $1.60B | +12.19% | 0.00% |
| TWO | 37.71% | $1.21B | -15.84% | 15.54% |
| UE | 37.59% | $2.93B | +40.88% | 2.86% |
| IIPR | 37.58% | $3.01B | +33.85% | 7.00% |
| PLRX | 37.55% | $778.32M | -9.55% | 0.00% |
| WD | 37.53% | $3.61B | +30.99% | 2.42% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RLI | 0.01% | $8.01B | +29.25% | 0.64% |
| COCO | 0.02% | $2.01B | +24.49% | 0.00% |
| APRE | 0.02% | $16.41M | -19.47% | 0.00% |
| FIZZ | -0.04% | $4.43B | +4.83% | 0.00% |
| QXO | 0.04% | $6.51B | -35.95% | 0.00% |
| CORZ | 0.06% | $4.60B | +3,201.26% | 0.00% |
| SOC | -0.09% | $1.93B | +74.70% | 0.00% |
| BYRN | -0.09% | $479.70M | +295.19% | 0.00% |
| CYD | -0.10% | $364.46M | -2.94% | 4.26% |
| AGX | -0.10% | $2.01B | +224.91% | 0.85% |
| BSM | -0.11% | $3.17B | -13.01% | 10.65% |
| ASR | -0.12% | $7.56B | +26.22% | 0.00% |
| HPK | -0.19% | $1.86B | -9.44% | 0.81% |
| NGS | -0.21% | $320.33M | +71.20% | 0.00% |
| TPST | -0.22% | $37.75M | -77.59% | 0.00% |
| PENG | 0.22% | $911.79M | +4.97% | 0.00% |
| SPR | 0.34% | $3.72B | +23.27% | 0.00% |
| VNOM | -0.39% | $5.48B | +79.62% | 3.35% |
| AMED | -0.41% | $2.95B | -3.95% | 0.00% |
| VERX | -0.44% | $7.99B | +89.70% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HUSA | -13.99% | $16.69M | -11.56% | 0.00% |
| CVM | -13.67% | $41.17M | -73.98% | 0.00% |
| TCTM | -11.65% | $8.10M | -42.99% | 0.00% |
| MNR | -10.76% | $1.66B | -10.71% | 15.90% |
| SOLV | -9.44% | $11.58B | -16.19% | 0.00% |
| AZO | -8.44% | $52.52B | +16.10% | 0.00% |
| STG | -8.41% | $35.67M | +7.92% | 0.00% |
| CYCN | -8.38% | $4.77M | -16.19% | 0.00% |
| MOH | -8.15% | $16.16B | -21.56% | 0.00% |
| PULM | -7.99% | $19.83M | +202.98% | 0.00% |
| IEP | -7.67% | $5.70B | -31.12% | 31.39% |
| VSTA | -7.49% | $204.94M | -39.33% | 0.00% |
| BP | -7.28% | $77.24B | -18.61% | 6.32% |
| OCX | -6.64% | $42.93M | -36.09% | 0.00% |
| LTM | -6.09% | $8.51B | -100.00% | <0.01% |
| BF.B | -6.07% | $19.01B | -31.35% | 2.18% |
| KSPI | -5.27% | $20.86B | +18.06% | 3.37% |
| CBOE | -5.12% | $21.46B | +15.84% | 1.11% |
| VERI | -4.98% | $111.67M | +35.81% | 0.00% |
| PRPO | -4.95% | $9.10M | -13.65% | 0.00% |
ETF's related to RVMD
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| KRBN | 0.12% | $242.47M | 0.85% |
| SHV | 0.43% | $18.13B | 0.15% |
| FBY | 0.58% | $127.69M | 0.99% |
| HDRO | 0.61% | $164.26M | 0.3% |
| SOYB | 0.93% | $27.32M | 0.22% |
| SGOV | -1.03% | $27.53B | 0.09% |
| ULST | 1.04% | $535.47M | 0.2% |
| JBBB | 1.06% | $1.26B | 0.49% |
| MINT | -1.07% | $11.62B | 0.35% |
| DBA | 1.38% | $755.88M | 0.93% |
| UNG | 1.68% | $908.80M | 1.06% |
| BILZ | -1.91% | $563.02M | 0.14% |
| XBIL | 1.96% | $637.70M | 0.15% |
| SEIX | -2.16% | $268.81M | 0.62% |
| CLOI | 2.37% | $715.40M | 0.4% |
| CORN | -2.45% | $61.12M | 0.2% |
| TBIL | -2.57% | $4.38B | 0.15% |
| DBMF | 2.96% | $1.02B | 0.85% |
| FMF | 3.11% | $244.61M | 0.95% |
| CSHI | 3.64% | $482.85M | 0.38% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -33.32% | $388.04M | 1.43% |
| VIXY | -28.69% | $195.31M | 0.85% |
| TAIL | -21.74% | $67.98M | 0.59% |
| TPMN | -16.58% | $40.60M | 0.65% |
| USDU | -15.04% | $201.97M | 0.5% |
| UUP | -12.88% | $309.25M | 0.77% |
| CTA | -9.91% | $350.27M | 0.78% |
| KMLM | -9.63% | $353.87M | 0.9% |
| DBE | -8.10% | $50.13M | 0.77% |
| EQLS | -7.96% | $76.08M | 1% |
| GSG | -7.54% | $914.42M | 0.75% |
| DBO | -7.01% | $217.57M | 0.77% |
| CANE | -6.37% | $17.72M | 0.29% |
| ICLO | -5.66% | $209.30M | 0.2% |
| BOXX | -5.04% | $4.43B | 0.1949% |
| KCCA | -4.97% | $220.51M | 0.87% |
| WEAT | -4.93% | $120.27M | 0.28% |
| TBIL | -2.57% | $4.38B | 0.15% |
| CORN | -2.45% | $61.12M | 0.2% |
| SEIX | -2.16% | $268.81M | 0.62% |
News
Yahoo
Insightful Analysis of Revolution Medicines Inc's Financial Health and Market Position
Yahoo
Revolution Medicines Inc (RVMD) reports promising clinical progress and robust cash reserves, despite increased R&D and administrative costs.
Yahoo
Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging safety, tolerability and antitumor activity in patients with PDAC harboring a KRAS G12D mutation Company on track to provide update on lung cancer programs in the fourth quarter of 2024 Revolution Medicines to hold webcast today at 4:30 p.m.
SeekingAlpha
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsRyan Asay â Senior Vice...
SeekingAlpha
The following slide deck was published by Revolution Medicines, Inc.
Finnhub
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.